Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets
Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.
BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).
BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.
About Optimus Pharma
Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.
More Stories
Why You Shouldn’t Rely on NAV When Selecting Mutual Funds
New Delhi (India), September 30: NAV stands for Net Asset Value, which refers to the cost of a single mutual...
“The Top 10 Companies 2023-2024: Unveiled Leading the Future of Business and Innovation!”
New Delhi (India), September 30: In the ever-evolving landscape of global business and innovation, the year 2023-2024 promises to be...
Clarivate Reveals the India Research Excellence – Citation Awards 2023
New Delhi (India), September 30: Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust...
Vishnusurya Projects and Infra Limited – IPO Opens on September 29, 2023
Mumbai (Maharashtra) [India], September 30: Vishnusurya Projects and Infra Limited, one of the leading players in the fields of construction, infrastructure development, mining, and aggregates, has announced...
42nd National Brainobrain Abacus Competition Festival 2023 in Chennai: A Triumph of Young Minds and Educational Excellence
Chennai (Tamil Nadu) [India], September 30: The 42nd National Brainobrain Abacus Competition Festival, a two-day extravaganza held on September 9th...
Plada Infotech Services Limited IPO Opens on 29th September, 2023 And listing on NSE Emerge
New Delhi (India), September 30: Plada Infotech Services Limited, specialize in delivering comprehensive Business Process Outsourcing (BPO) services, has announced its...
Average Rating